- Home
- EFR vs RIGL Comparison
EFR vs RIGL Comparison
Compare EFR & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFR
- RIGL
- Stock Information
- Founded
- EFR 2003
- RIGL 1996
- Country
- EFR United States
- RIGL United States
- Employees
- EFR N/A
- RIGL N/A
- Industry
- EFR Trusts Except Educational Religious and Charitable
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- EFR Finance
- RIGL Health Care
- Exchange
- EFR Nasdaq
- RIGL Nasdaq
- Market Cap
- EFR 344.0M
- RIGL 335.5M
- IPO Year
- EFR N/A
- RIGL 2000
- Fundamental
- Price
- EFR $11.71
- RIGL $38.85
- Analyst Decision
- EFR
- RIGL Buy
- Analyst Count
- EFR 0
- RIGL 5
- Target Price
- EFR N/A
- RIGL $38.20
- AVG Volume (30 Days)
- EFR 88.6K
- RIGL 995.6K
- Earning Date
- EFR 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- EFR 9.43%
- RIGL N/A
- EPS Growth
- EFR N/A
- RIGL N/A
- EPS
- EFR 1.69
- RIGL 5.43
- Revenue
- EFR N/A
- RIGL $267,921,000.00
- Revenue This Year
- EFR N/A
- RIGL $59.93
- Revenue Next Year
- EFR N/A
- RIGL N/A
- P/E Ratio
- EFR $7.74
- RIGL $7.15
- Revenue Growth
- EFR N/A
- RIGL 105.62
- 52 Week Low
- EFR $10.95
- RIGL $12.66
- 52 Week High
- EFR $13.29
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- EFR 43.60
- RIGL 68.57
- Support Level
- EFR $11.64
- RIGL $39.00
- Resistance Level
- EFR $11.79
- RIGL $42.08
- Average True Range (ATR)
- EFR 0.09
- RIGL 2.32
- MACD
- EFR 0.01
- RIGL -0.37
- Stochastic Oscillator
- EFR 60.00
- RIGL 53.26
About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.